FOXO3 restores autophagy flux and attenuates the activation of the NLRP3 inflammasome in Kupffer cells by promoting the transcription of Bim (BCL2L11) [66], suggesting that this could be a potential therapeutic target in non-alcoholic fatty liver disease and other obesity-related diseases. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.